Biotech Updates: Acrivon CLIA Lab, Lilly M&A Spree, Defence Radiopharma COO
Acrivon launched a CLIA-certified lab. Eli Lilly disclosed over 5 trillion won in M&A and licensing. Defence Therapeutics named a new radiopharmaceutical COO.
Olix Pharmaceuticals
CompanyAlso known as: OliX Pharmaceuticals
Company Profile
Olix Pharmaceuticals is a clinical-stage biotechnology company developing RNA interference therapeutics and platform technologies for multiple diseases.
- Website
- https://www.olixpharma.com
- Headquarters
- Suwon, Gyeonggi-do, South Korea
- Founded
- 2010
- Stock Ticker
- KOSDAQ:226950
Related News
Galux raises $29 million and partners with OliX on AI-based siRNA delivery
Galux completed a $29 million Series B financing and entered an MOU with OliX Pharmaceuticals to jointly develop a next-generation AI-based siRNA delivery platform. The funding will support GaluxDesign, R&D expansion and preclinical validation.
New Hair Loss Drugs Target Growth Pathways, Avoid Hormone Suppression Side Effects
Pharmaceutical companies are developing innovative hair loss treatments that directly activate hair growth pathways rather than suppressing male hormones, with several candidates entering clinical trials and promising enhanced safety profiles.